Developing game changing treatments and cell therapies for severe diseases
We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.
“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”
Professor Ann Logan,
Scientific Director, Neuregenix Ltd.
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
First patient treated with ILB in TIKOMED’s clinical trial for ALS
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
TIKOMED WILL BE SENDING TEAM TO EAST/WEST CEO MEETING & BIOTECH SHOWCASE